Cargando…
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
Second-line treatment of endometrial cancer is an unmet medical need. Lurbinectedin showed promising antitumor activity in a phase I study in combination with doxorubicin in advanced endometrial cancer. This phase 2 Basket trial evaluated lurbinectedin 3.2 mg/m(2) 1-h intravenous infusion every 3 we...
Autores principales: | Kristeleit, Rebecca, Leary, Alexandra, Delord, Jean Pierre, Moreno, Victor, Oaknin, Ana, Castellano, Daniel, Shappiro, Geoffrey I., Fernández, Cristian, Kahatt, Carmen, Alfaro, Vicente, Siguero, Mariano, Rueda, Daniel, Zeaiter, Ali, Awada, Ahmad, Santaballa, Ana, Zaman, Khalil, Sehouli, Jalid, Subbiah, Vivek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560193/ https://www.ncbi.nlm.nih.gov/pubmed/37556023 http://dx.doi.org/10.1007/s10637-023-01383-2 |
Ejemplares similares
-
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study
por: Boni, V., et al.
Publicado: (2022) -
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
por: Subbiah, Vivek, et al.
Publicado: (2022) -
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study
por: Kristeleit, Rebecca, et al.
Publicado: (2021) -
Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer
por: Awada, A.H., et al.
Publicado: (2022) -
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
por: Calvo, Emiliano, et al.
Publicado: (2022)